Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
Graduate School of Health Science Business Convergence, Chungbuk National University, Cheongju, Korea.
J Korean Med Sci. 2019 Jul 1;34(25):e176. doi: 10.3346/jkms.2019.34.e176.
The numbers of patients on dialysis and their life expectancies are increasing. Reduced renal function is associated with an increased risk of cancer, but the cancer incidence and sites in dialysis patients compared with those of the general population require further investigation. We investigated the incidences of various cancers in dialysis patients in Korea and used national health insurance data to identify cancers that should be screened in dialysis clinics.
We accessed the Korean National Health Insurance Database and excerpted data using the International Classification of Disease codes for dialysis and malignancies. We included all patients who commenced dialysis between 2004 and 2013 and selected the same number of controls via propensity score matching.
A total of 48,315 dialysis patients and controls were evaluated; of these, 2,504 (5.2%) dialysis patients and 2,201 (4.6%) controls developed cancer. The overall cancer risk was 1.54-fold higher in dialysis patients than in controls (adjusted hazard ratio, 1.71; 95% confidence interval, 1.61-1.81). The cancer incidence rate (incidence rate ratio [IRR], 3.27) was especially high in younger dialysis patients (aged 0-29 years). The most common malignancy of end-stage renal disease patients and controls was colorectal cancer. The major primary cancer sites in dialysis patients were liver and stomach, followed by the lung, kidney, and urinary tract. Kidney cancer exhibited the highest IRR (6.75), followed by upper urinary tract (4.00) and skin cancer (3.38). The rates of prostate cancer (0.54) and oropharyngeal cancer (0.72) were lower than those in the general population.
Dialysis patients exhibited a higher incidence of malignancy than controls. Dialysis patients should be screened in terms of colorectal, liver, lung, kidney and urinary tract malignancies in dialysis clinics.
接受透析治疗的患者人数及其预期寿命都在增加。肾功能下降与癌症风险增加相关,但在透析患者与普通人群中,癌症的发病率和发病部位仍需要进一步研究。本研究旨在调查韩国透析患者的各种癌症发病率,并利用国家健康保险数据,确定在透析诊所应筛查的癌症。
我们查阅了韩国国家健康保险数据库,并使用国际疾病分类代码获取了透析和恶性肿瘤的数据。我们纳入了 2004 年至 2013 年间开始透析的所有患者,并通过倾向评分匹配选择了相同数量的对照组。
共评估了 48315 例透析患者和对照组;其中,2504 例(5.2%)透析患者和 2201 例(4.6%)对照组发生了癌症。与对照组相比,透析患者的总体癌症风险增加了 1.54 倍(调整后的危险比,1.71;95%置信区间,1.61-1.81)。在年轻的透析患者(年龄 0-29 岁)中,癌症的发病率(发病率比,3.27)尤其高。终末期肾病患者和对照组中最常见的恶性肿瘤是结直肠癌。透析患者的主要原发性癌症部位是肝脏和胃部,其次是肺部、肾脏和泌尿道。与对照组相比,肾脏癌的发病率比最高(6.75),其次是上尿路(4.00)和皮肤癌(3.38)。前列腺癌(0.54)和口咽癌(0.72)的发病率低于普通人群。
与对照组相比,透析患者的恶性肿瘤发病率更高。在透析诊所中,应针对结直肠、肝脏、肺部、肾脏和泌尿道恶性肿瘤对透析患者进行筛查。